Used in targeted therapies for hematological malignancies due to its specific binding to CD45 (PTPRC), a marker widely expressed on leukocytes. This antibody serves as a key component in antibody-drug conjugates (ADCs) and radioimmunotherapy, enabling selective delivery of cytotoxic agents or radiation to cancerous blood cells while sparing healthy tissues. Its high specificity supports applications in conditioning regimens prior to hematopoietic stem cell transplantation, where it helps deplete abnormal immune cells. Additionally, it is employed in diagnostic and minimal residual disease detection assays in leukemia and lymphoma due to its consistent expression on malignant lymphoid and myeloid cells.